71 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/505009/roches-tecentriq-combo-gets-eu-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-505009 Sep 06, 2019 - The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study http://www.zacks.com/stock/news/505271/bristol-myers-bmy-opdivo-falls-flat-in-brain-tumor-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-505271 Sep 06, 2019 - Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs http://www.zacks.com/stock/news/505264/pharma-stock-roundup-agns-opioid-settlement-line-extension-nod-in-eu-for-mrk-jnj-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-505264 Sep 06, 2019 - Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study http://www.zacks.com/stock/news/509890/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509890 Sep 09, 2019 - Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug http://www.zacks.com/stock/news/514866/roche-rhhby-reports-positive-data-on-tecentriq-ms-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-514866 Sep 12, 2019 - Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised) http://www.zacks.com/stock/news/516412/roche-reports-positive-data-on-tecentriq-nmosd-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-516412 Sep 13, 2019 - Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
Renal Cell Carcinoma Space in Focus: Some Key Developments http://www.zacks.com/stock/news/516791/renal-cell-carcinoma-space-in-focus-some-key-developments?cid=CS-ZC-FT-analyst_blog|industry_focus-516791 Sep 13, 2019 - The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert http://www.zacks.com/stock/news/520833/breast-cancer-drugs-may-inflame-lungs-per-fda-safety-alert?cid=CS-ZC-FT-analyst_blog|industry_focus-520833 Sep 16, 2019 - The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma http://www.zacks.com/stock/news/524596/mercks-keytruda-combo-gets-fda-nod-for-endometrial-carcinoma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-524596 Sep 18, 2019 - Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
2 Pharma Stocks You Should Buy Now https://www.fool.com/investing/2019/09/21/2-pharma-stocks-you-should-buy-now.aspx?source=iedfolrf0000001 Sep 21, 2019 - Both Vertex and Merck dominate their respective segments of the pharmaceutical market.

Pages: 12345678

<<<Page 4>